Suppr超能文献

双向增加 B 细胞淋巴瘤和 T 细胞淋巴瘤的风险。

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.

机构信息

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD; and.

出版信息

Blood. 2021 Sep 2;138(9):785-789. doi: 10.1182/blood.2020010497.

Abstract

Lymphoma survivors have a significantly higher risk of developing second primary lymphoma than the general population; however, bidirectional risks of developing B- and T-cell lymphomas (BCLs and TCLs) specifically are less well understood. We used population-based cancer registry data to estimate the subtype-specific risks of second primary lymphoma among patients with first BCL (n = 288 478) or TCL (n = 23 747). We observed nearly fivefold increased bidirectional risk between BCL and TCL overall (TCL following BCL: standardized incidence ratio [SIR] = 4.7, 95% confidence interval [CI] = 4.2-5.2; BCL following TCL: SIR = 4.7, 95% CI = 4.1-5.2), but the risk varied substantially by lymphoma subtype. The highest SIRs were observed between Hodgkin lymphoma (HL) and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) (PTCL-NOS following HL: SIR = 27.5; HL following PTCL-NOS: SIR = 31.6). Strikingly elevated risks also were notable for angioimmunoblastic T-cell lymphoma (AITL) and diffuse large B-cell lymphoma (DLBCL) (AITL following DLBCL: SIR = 9.7; DLBCL following AITL: SIR = 15.3). These increased risks were strongest within the first year following diagnosis but remained persistently elevated even at ≥5 years. In contrast, SIRs were <5 for all associations of TCL with chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. These patterns support etiologic heterogeneity among lymphoma subtypes and provide further insights into lymphomagenesis.

摘要

淋巴瘤幸存者发生第二原发性淋巴瘤的风险明显高于普通人群;然而,B 细胞和 T 细胞淋巴瘤(BCL 和 TCL)双向发病风险的了解较少。我们使用基于人群的癌症登记数据来估计首次 BCL(n=288478)或 TCL(n=23747)患者中第二原发性淋巴瘤的亚型特异性风险。我们观察到总体上 BCL 和 TCL 之间双向风险增加近五倍(TCL 继 BCL 之后:标准化发病比 [SIR] = 4.7,95%置信区间 [CI] = 4.2-5.2;BCL 继 TCL 之后:SIR = 4.7,95% CI = 4.1-5.2),但风险差异很大。HL 与外周 T 细胞淋巴瘤非特指型(PTCL-NOS)之间的 SIR 最高(PTCL-NOS 继 HL 之后:SIR = 27.5;HL 继 PTCL-NOS 之后:SIR = 31.6)。血管免疫母细胞性 T 细胞淋巴瘤(AITL)和弥漫性大 B 细胞淋巴瘤(DLBCL)之间也明显存在显著升高的风险(AITL 继 DLBCL 之后:SIR = 9.7;DLBCL 继 AITL 之后:SIR = 15.3)。这些增加的风险在诊断后第一年最强,但即使在≥5 年后仍持续升高。相比之下,TCL 与慢性淋巴细胞白血病/小淋巴细胞淋巴瘤和滤泡性淋巴瘤之间的所有关联的 SIR 均<5。这些模式支持淋巴瘤亚型之间的病因异质性,并提供了对淋巴瘤发生的进一步了解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f101/8414260/bc3b9193dbba/bloodBLD2020010497absf1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验